axiebet88 voucher code

axiebet88 voucher code The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in their portfolios with a new year starting, either. Three Motley Fool contributors think they have found stocks that could provide a big bang for growth investors . Here's why they believe Novo Nordisk ( NVO -0.32% ) , Summit Therapeutics ( SMMT -5.55% ) , and Viking Therapeutics ( VKTX -3.56% ) could be monster winners for 2025. Novo Nordisk could be due for a big comeback in 2025 David Jagielski (Novo Nordisk): It's been a tough 2024 for drugmaker Novo Nordisk. Entering this week, its shares were down 14% as the company behind the popular diabetes drug Ozempic has been generating good growth, but that hasn't been enough to win over investors. To make things worse, the company recently unveiled results from a trial involving weight loss treatment CagriSema. In a late-stage trial, the drug helped participants lose an average of 22.7% of their weight, versus the 25% that was expected. The stock fell by around 20% on the news in what looked to be a gross overreaction about what may still be the top weight loss drug in the future. The company already has an approved weight loss treatment in Wegovy, which shares the same active ingredient (semaglutide) with Ozempic. CagriSema's trial results were by no means awful, but the market has already responded in a big (negative) way. The sell-off in the stock has pushed it near its 52-week low, and it's now trading at 22 times next year's estimated future earnings (based on analyst estimates). Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could generate monster gains next year as a rebound could be in the cards. Novo Nordisk has been investing in additional manufacturing capacity to help meet the surging demand for its weight loss and diabetes treatments, and its results have been great in recent quarters. The business has been growing its operating profit by 21% through the first nine months of this year. And with a lot more growth still ahead for the business, investors should be careful not to overlook Novo Nordisk -- the healthcare stock could have plenty of upside next year. A potential blockbuster on the way Keith Speights (Summit Therapeutics): 2024 has been a fantastic year for Summit Therapeutics, with its stock delivering an explosive 7x gain. I think the new year will bring more good fortune for this up-and-coming drugmaker. Summit expects to announce top-line results in mid-2025 from a phase 3 study evaluating ivonescimab in combination with chemotherapy as a second-line treatment for advanced non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) has already granted Fast Track Designation to the therapy for this indication. This means the approval process could be expedited and guarantees the FDA will work closely with Summit on advancing ivonescimab. To be sure, there's a degree of risk associated with any clinical trial. However, Summit's chances of success with this late-stage study appear to be great. Why? The company's partner, Chinese pharmaceutical company Akeso , reported spectacular results from its phase 3 study of ivonescimab earlier this year as a first-line treatment for NSCLC. Patients receiving the drug experienced significantly increased progression-free survival rates than patients receiving Merck 's Keytruda immunotherapy. It's important to note that Keytruda ranked as the world's top-selling drug last year with sales of $25 billion. With ivonescimab outperforming Keytruda in Akeso's late-stage study, I predict Summit will have a blockbuster drug on its hands in the not-too-distant future. And Summit won't be content with the second-line NSCLC indication. The company is evaluating ivonescimab in combination with chemotherapy in a late-stage study as a first-line NSCLC therapy. It also plans to initiate another phase 3 study of the drug as a monotherapy in the first-line NSCLC setting. Lightning can strike the same place twice Prosper Junior Bakiny (Viking Therapeutics): Can a stock deliver monster returns two years in a row? Under the right conditions, the answer is yes. Consider Viking Therapeutics, a mid-cap biotech that soared this year following excellent phase 2 results for its investigational weight loss medicine, VK2735. The company should make progress on this program next year, when it will probably start a phase 3 study. It is also working on an investigational medicine for metabolic dysfunction-associated steatohepatitis, which should also enter pivotal trials in 2025. Viking has more promising early-stage candidates, and progress from those could be what jolts the stock price. Its oral formulation of VK2735 is a good example. Billion-dollar weight loss medicines like Zepbound and Wegovy are administered via injection. An oral formulation would be a welcome sight for many patients. Although several drugmakers are working on this project , Viking has more upside potential than the large leading pharmaceutical companies, while smaller ones haven't shown the kinds of results it has so far. And the company is still working on promising anti-obesity programs. It recently reported encouraging pre-clinical results from a brand-new clinical compound. Viking is looking to establish itself as a leader in this therapeutic area, which happens to be the hottest and one of the fastest-growing in the industry. It has shown more promise in the field than most other companies, even those with far more resources than it has. So, Viking Therapeutics' shares could once again soar next year and deliver strong performance in the next half-decade.

Romania's top court annuls first round of presidential vote won by far-right candidate

Washington’s roster got a whole lot younger on Wednesday. The Huskies signed 29 commitments for the 2025 season during the first day of the early signing period. Coach Jedd Fisch currently has 62 scholarships committed to players who are sophomores by eligibility or younger. Fisch and the Huskies can add some experience to their roster starting on Monday, when the transfer portal opens. Washington will also have more attrition of its own because the Huskies are above the self-imposed 85-scholarship limit Fisch announced on Wednesday. Here are five position groups the Huskies might target in the transfer portal starting on Monday. This probably has to be Washington’s top priority in the transfer portal. The Huskies lose their top-two defensive tackles — Sebastian Valdez and Jacob Bandes — after the bowl game, leaving them with a young, unproven group at the position. Logan Sagapolu played offensive line for the first four years of his college career. Jayvon and Armon Parker are coming off season-ending injuries. Bryce Butler, a junior college addition this season, played in three games because of injuries and redshirted to preserve a year of eligibility. Elinneus Davis had 14 tackles, two tackles for a loss, a sack and a pass breakup, and finished his first season as a contributor ranked third in snaps among defensive tackles according to Pro Football Focus. UW also has 6-foot-3, 296-pound Omar Khan who redshirted as a true freshman in 2024. The Huskies signed 315-pound Dominic Macon and 260-pound Caleb Smith in their 2025 recruiting class but they will likely need to redshirt in 2025. Fisch heavily implied Washington will hunt the portal for more defensive linemen while speaking during his signing day news conference on Wednesday. “In the transfer portal, in terms of defensive linemen, you have to be able to take the older players.” Washington signed three linebackers as part of its 2025 recruiting class, including local four-star prospects Zaydrius Rainey-Sale and Jonathan Epperson Jr. But after losing captains Alphonzo Tuputala and Carson Bruener and standout special teamer Drew Fowler, it makes sense to add another linebacker with more experience to the room. Anthony Ward, a former walk-on who Fisch gave a scholarship to at Arizona, is the oldest player in the group. Khmori House, however, is the most experienced. The Southern Californian played in all 12 games as a true freshman in 2024, racking up 35 tackles, a forced fumble and an interception. He's a presumed starter for 2025 and Fisch has repeatedly called House the future of the defense. Deven Bryant and Hayden Moore, who will both be third-year sophomores in 2025, saw limited action this season. Bryant had a prolific high school careers at St. John Bosco High School, where he played with House, but has been hampered by injuries since arriving at UW in 2023. Moore was a Michigan transfer who appeared primarily on special teams in 2024. Similar to linebacker, Washington loses captain Kamren Fabiculanan, who led UW’s defense with 736 snaps this season. Cameron Broussard also departs, along with veteran special teamer Justin Harrington. Makell Esteen still has eligibility, and the Huskies have a young group of second-year safeties in Peyton Waters, Paul Mencke Jr., Rahshawn Clark and Rahim Wright II. Waters burned his redshirt in 2024, mainly as a special teamer, and will be a sophomore in 2025 while Mencke, Clark and Wright will all be redshirt freshmen. Clark was a cornerback at Garfield High School but is listed as a safety on UW’s roster. The Huskies also signed four-star freshman Rylon Dillard-Allen on Wednesday. Between Esteen and the second-year safeties, however, there isn’t much depth. Fisch has been high on Vincent Holmes, a third-year sophomore in 2025, despite the Bay Area native’s special teams gaffe against Rutgers. Holmes was UW’s third safety during games when Esteen or Broussard were unavailable because of injury. Sumner native Tristan Dunn is the final safety on the roster, playing almost exclusively on special teams in 2024. He’ll be entering his fourth season in the program in 2025. Bringing in a veteran safety to pair primarily with Esteen makes some sense, especially because defensive coordinator Steve Belichick likes to use three-safety looks. Washington’s offensive line issues were apparent all season, yet Fisch has been adamant that the Huskies will build their new offensive line through high school recruiting. UW signed six offensive linemen as part of their 2025 recruiting class: Champ Taulealea, John Mills, Jake Flores, Peter Langi, Jack Shaffer and Lowen Colman-Brusa. The Huskies currently have 18 offensive linemen on scholarship, assuming no attrition. Offensive coordinator Brennan Carroll, who also coaches the offensive line, has previously said he’d like to have around 16 scholarship linemen on the roster. But on Friday, Arizona left guard Wendell Moe Jr. announced he intends to enter the transfer portal. The third-year sophomore started 13 games for Fisch and Carroll at left guard in 2023, then maintained his spot after staying with the Wildcats in 2024. PFF graded the 6-2, 339-pound Moe as Arizona’s best pass-blocking lineman who played at least three games. He didn’t allow a single sack in 491 pass-blocking snaps in 2024. Washington signed five wide receivers for its 2025 class, but the Huskies will lose Giles Jackson and Jeremiah Hunter — who combined for 107 catches and 1,144 receiving yards — after the bowl game. Additionally Denzel Boston is eligible for the NFL draft after finishing his third season of college football in 2024. The rest of UW’s receiver group has limited experience. Rashid Williams and Keith Reynolds, both third-year sophomores in 2025, were rotational players during the past season. Williams had 10 catches for 119 yards and a touchdown, while Reynolds was UW’s primary kick returner and scored his first touchdown on a rush against USC. Audric Harris burned his redshirt as a true freshman, making one catch for seven yards while appearing in seven games. UW also has Kevin Green Jr., an Arizona transfer who will be a fourth-year junior but missed the entire 2024 campaign with an injury. Green had eight catches for 97 yards with the Wildcats in 2023. The seven other receivers on the roster — five true freshmen and second-year receivers Jason Robinson Jr. and Justice Williams — have never played a college snap. If Washington doesn't add a veteran receiver, they’ll be counting on Green, Williams and Reynolds to really step up alongside Boston.Michigan aims to cap lost season by beating Ohio State

John Lewis pins its hopes on a bumper Black Friday as it brings back its 'never knowingly undersold' pledge